Redeye provides its initial take on Vitec’s Q4 2022 report, which came in broadly above our estimate...
Redeye retains its positive view on Lagercrantz following a Q3 report with 10% organic growth and he...
NAV up for tenth straight quarter +3% return driven by +4% in NAV, discount +1pp NAV discount at 31%...
Watch out for the SolidEngineer changes Major estimate changes following recent events 10x '23e adj.
Q4 report due on Wednesday, 8 February Lower FX and more cautious on margin recovery timeline 15x '2...
FY'23 guidance indicates slow margin pick-up CMD in March should confirm intact LT outlook Fair valu...
Stark omsättning, men orderingång åt det svagare hållet Nettoomsättningen för Q4 2022 uppgick till 8...
A company undergoing transformation Since Starboard became the main shareholder of Maha at the end o...
Fellow Bank has met the expectations that were set out for 2022.
Redeye reinforces its positive view of ADDvise following strong preliminary Q4 figures.
Solid Q4 top-line, but margins fail to reach expectations FY'23 guidance indicates a soft margin exp...
For yet another quarter, Nexam was hurt by slow demand in the wind power industry.
Q4 report on Thursday, 16 February Stronger winds, but again below budget EBIT of SEK 51m, with a ma...
Q4 report due on Thursday, 16 February Sale of Centennial Flats expected to be the main EBIT driver ...
LL Lucky Games meddelade den 30 januari att bolagsstämman beslutat om genomförandet av den tidigare ...
Redeye updates its view on the lawsuit with a new schedule and an updated view on the number of unit...
Redeye makes slight estimate changes ahead of the Q4 report (due 10th of February).
Redeye leaves a comment on Faron Pharmaceutical's recent private placement.
Redeye raises its Base Case slightly following the positive conclusion of the phase I trial with laq...
Redeye is pleased to note that Lifeclean did a direct issue of SEK 27m after costs this morning.
